InMed to Present at 18th Annual Rodman and Renshaw Global Investment Conference

VANCOUVER, Sept. 12, 2016 /CNW/ - InMed Pharmaceuticals, Inc. ("InMed") (CSE: IN; OTCQB: IMLFF), a biopharmaceutical company specializing in the research and development of novel, cannabinoid-based drug therapies, announced today that it will present at the Rodman & Renshaw 18th Annual Global Investment/Healthcare Conference. The Conference will be held September 11-13, 2016 at the Lotte New York Palace Hotel, New York City.


Rodman & Renshaw 18th Annual Global Investment Conference 


Tuesday, September 13, 2016 


Lotte New York Palace Hotel


5:30 PM (EST) in Roswell Room (4th Floor)


William Garner M.D., a Director of InMed Pharmaceuticals, will present a corporate overview, recent business highlights and update on drug development plans.

About Rodman & Renshaw Conferences, LLC

The Rodman & Renshaw 18th Annual Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC, will host 300 companies will be presenting their businesses to an audience of approximately 2,000 attendees.  The conference will focus on tracks dedicated to Healthcare; Natural Resources; Technology; Media and Telecommunications; and, Cleantech. This year's conference will bring growth companies together with a vast audience and strategic investors. In addition to corporate presentations, Rodman facilitates one-on-one investor meetings and provides platforms for engaged Q&A sessions and daily networking opportunities.  

About InMed

InMed is a pre-clinical stage biopharmaceutical company that specializes in developing novel therapies through the research and development into the extensive pharmacology of cannabinoids coupled with innovative drug delivery systems. InMed's proprietary in silico drug/disease targeting platform, cannabinoid biosynthesis technology and drug development pipeline are the fundamental value drivers of the Company. For more information, visit

Cautionary Note Regarding Forward-Looking Information

Forward Looking Statements
This news release may contain forward-looking statements and information based on current expectations.  These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management's reasonable assumptions, there can be no assurance that such assumptions will prove to be correct.  We assume no responsibility to update or revise them to reflect new events or circumstances.

Additionally, there are known and unknown risk factors which could cause InMed Pharmaceuticals actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein. 

All forward-looking information herein is qualified in its entirety by this cautionary statement, and InMed Pharmaceuticals disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.

These risks and uncertainties include, among others, the possibility that clinical trials will not be successful, or be completed, or confirm earlier clinical trial results, risks associated with obtaining funding from third parties, risks related to the timing and costs of clinical trials and the receipt of regulatory approvals.



SOURCE InMed Pharmaceuticals Inc.

For further information: InMed Pharmaceuticals Inc.: Chris Bogart, SVP, Investor Relations and Corporate Strategy, T: 604.669.7207, E: